Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 2/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 5/20 | 0.40 |
| ▸ | MME | P08473 | 3/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30408803 | 0.97 | PTPN1 (0.45) | GNPATBACE1CTSDLTA4HPTPN1 | |
| SCHEMBL30799921 | 0.97 | PTPN1 (0.45) | GNPATBACE1CTSDLTA4HPTPN1 | |
| SCHEMBL30090922 | 0.93 | BACE1 (0.47) | GNPATBACE1CTSDPTPN1MME | |
| SCHEMBL31064820 | 0.92 | BACE1 (0.49) | GNPATBACE1CTSDLTA4HPTPN1 | |
| SCHEMBL4957790 | 0.91 | LTA4H (0.49) | LTA4HDPP4DPP8DPP9MME | |
| SCHEMBL2807590 | 0.91 | LTA4H (0.49) | LTA4HDPP4DPP8DPP9MME | |
| SCHEMBL10494263 | 0.91 | LTA4H (0.49) | LTA4HDPP4DPP8DPP9MME | |
| SCHEMBL3341838 | 0.91 | LTA4H (0.49) | LTA4HDPP4DPP8DPP9MME | |
| SCHEMBL29630727 | 0.91 | BACE1 (0.54) | BACE1CTSDENPEP | |
| SCHEMBL3341843 | 0.91 | LTA4H (0.49) | LTA4HDPP4DPP8DPP9MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912785-B2 | Peptide compositions for slowing degradation of vitamin mineral supplements, foods, pharmaceutical and cosmetics | BAILEY STEVEN W (US) | 2024-02-27 | — | — | US | claimed |
| US-20240247028-A1 | PEPTIDE COMPOSITIONS FOR SLOWING DEGRADATION OF VITAMIN MINERAL SUPPLEMENTS, FOODS, PHARMACEUTICAL AND COSMETICS | BAILEY STEVEN W (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
| US-11912785-B2 | Peptide compositions for slowing degradation of vitamin mineral supplements, foods, pharmaceutical and cosmetics | BAILEY STEVEN W (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | GNPAT 3689/4885BACE1 10/4885CTSD 2704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.